TROX-1 is a drug which acts as a potent blocker of the Ca<sub>v</sub>2 type calcium channels. It was developed as a potential analgesic after the discovery that the selective Ca<sub>v</sub>2.2 blocker ziconotide is an active analgesic with similar efficacy to strong opioid drugs. Unlike ziconotide, TROX-1 is not so selective, and also blocks the Ca<sub>v</sub>2.1 and Ca<sub>v</sub>2.3 calcium channel subtypes, but it has the great advantage of being orally active, whereas ziconotide must be administered intrathecally, by injection into the spinal fluid. In animal studies of TROX-1, analgesic effects were observed with similar efficacy to NSAIDs such as naproxen or diclofenac, and anti-allodynia effects equivalent to pregabalin or duloxetine.